S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

$3.15
-0.36 (-10.26%)
(As of 02/21/2024 ET)
Today's Range
$3.00
$3.45
50-Day Range
$1.95
$4.04
52-Week Range
$1.91
$32.87
Volume
2.26 million shs
Average Volume
3.39 million shs
Market Capitalization
$95.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.13

BioXcel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
570.6% Upside
$21.13 Price Target
Short Interest
Healthy
11.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.00mentions of BioXcel Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.16) to ($2.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

79th out of 932 stocks

Pharmaceutical Preparations Industry

27th out of 429 stocks


BTAI stock logo

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Stock Price History

BTAI Stock News Headlines

UBS Downgrades BioXcel Therapeutics (BTAI)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
BioXcel Therapeutics just downgraded at UBS, here's why
BTAI Mar 2024 5.000 put
BTAI Mar 2024 2.500 call
BTAI Mar 2024 3.000 put
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
BTAI Mar 2024 7.500 put
BioXcel Therapeutics Terminates $60 Mln Proposed Public Offering
Why BioXcel Therapeutics Shares Are Falling Today
Why Are Crypto Stocks Up Today?
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics Commences $60 Mln Public Offering; Stock Drops
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
2/21/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
183
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$21.13
High Stock Price Target
$40.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+648.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
7 Analysts

Profitability

Net Income
$-165,760,000.00
Net Margins
-17,037.44%
Pretax Margin
-17,037.60%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$2.74 per share

Miscellaneous

Free Float
19,505,000
Market Cap
$95.70 million
Optionable
Optionable
Beta
0.50

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 63)
    Founder, CEO, President, & Director
    Comp: $1.76M
  • Mr. Javier Rodriguez (Age 52)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $638.88k
  • Mr. Matthew Wiley (Age 52)
    Senior VP & Chief Commercial Officer
    Comp: $620.12k
  • Mr. Richard I. Steinhart MBA (Age 67)
    Senior VP & CFO
    Comp: $404k
  • Dr. Frank D. Yocca Ph.D. (Age 68)
    Senior VP & Chief Scientific Officer
    Comp: $452.58k
  • Dr. Vincent J. O'Neill B.Sc. (Age 55)
    M.D., M.R.C.P., Executive VP, Chief of Product Development & Medical Officer
    Comp: $510.17k
  • Dr. Chetan D. Lathia Ph.D.
    Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience
  • Mr. Robert Scala (Age 55)
    Vice President of Commercial Operations & Launch Planning
  • Dr. Friso Postma
    Senior Director of Neuroscience & Artificial intelligence














BTAI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they expect the company's stock price to reach $21.13 in the next year. This suggests a possible upside of 570.6% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2024?

BioXcel Therapeutics' stock was trading at $2.95 on January 1st, 2024. Since then, BTAI shares have increased by 6.8% and is now trading at $3.15.
View the best growth stocks for 2024 here
.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 2,460,000 shares, a drop of 17.4% from the January 15th total of 2,980,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 11.9% of the company's stock are short sold.
View BioXcel Therapeutics' Short Interest
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by $0.11. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.42 million. BioXcel Therapeutics had a negative net margin of 17,037.44% and a negative trailing twelve-month return on equity of 890.63%. The firm's quarterly revenue was up 45600.0% compared to the same quarter last year. During the same period last year, the business earned ($1.35) earnings per share.

What ETF holds BioXcel Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.59%), Charles Schwab Investment Management Inc. (0.63%), Citadel Advisors LLC (0.00%), Pennant Investors LP (0.28%), Cambridge Investment Research Advisors Inc. (0.13%) and DAVENPORT & Co LLC (0.12%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTAI) was last updated on 2/22/2024 by MarketBeat.com Staff